Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Minimization: a new method of assigning patients to treatment and control groups.

Taves DR.

Clin Pharmacol Ther. 1974 May;15(5):443-53. No abstract available.

PMID:
4597226
2.

Ineffectiveness of fluoride therapy in multiple myeloma.

Harley JB, Schilling A, Glidewell O.

N Engl J Med. 1972 Jun 15;286(24):1283-8. No abstract available.

PMID:
4554243
3.
4.

[Effects of pamidronate disodium (Bonin) combined with chemotherapy on bone pain in multiple myeloma].

Leng Y, Chen SL, Shi HZ.

Space Med Med Eng (Beijing). 2002 Oct;15(5):377-8. Chinese.

PMID:
12449148
5.

[Fluoride treatment of metabolic and malignant skeletal diseases].

Andersson KE, Berg B.

Lakartidningen. 1970 Apr 13;67:Suppl 1:46-55. Swedish. No abstract available.

PMID:
5478983
6.

[Multiple myeloma of the bone].

Facon T.

Rev Prat. 2002 Jan 1;52(1):63-70. French. No abstract available.

PMID:
11852769
7.

New approach to the treatment of bone disease with fluoride.

Taves DR.

Fed Proc. 1970 May-Jun;29(3):1185-7. No abstract available.

PMID:
4910268
8.

Multiple myeloma: effect of daily dichloromethylene bisphosphonate on skeletal complications.

Clemens MR, Fessele K, Heim ME.

Ann Hematol. 1993 Mar;66(3):141-6.

PMID:
8471660
9.

[Light chain myeloma: clinical study and prognostic factors ].

Redón J, Caballero M, Herranz C.

Med Clin (Barc). 1982 Jun 16-30;79(2):54-8. Spanish. No abstract available.

PMID:
6811809
10.

Biochemical assessment of bone disease in multiple myeloma.

Stĕpán JJ, Neuwirtová R, Pacovský V, Formánková J, Silinková-Málková E.

Clin Chim Acta. 1984 Sep 29;142(2):203-9.

PMID:
6499205
11.

[Multiple myeloma. Clinical review of 56 cases].

López Alvarez J, Sanz Marca A, Aboin Massieu FJ.

Rev Clin Esp. 1983 Nov 15;171(3):175-8. Spanish. No abstract available.

PMID:
6669751
12.

Myeloma bone disease.

Berenson JR.

Best Pract Res Clin Haematol. 2005;18(4):653-72. Review.

PMID:
16026743
13.

Advances in biology and therapy of multiple myeloma.

Barillé-Nion S, Barlogie B, Bataille R, Bergsagel PL, Epstein J, Fenton RG, Jacobson J, Kuehl WM, Shaughnessy J, Tricot G.

Hematology Am Soc Hematol Educ Program. 2003:248-78. Review.

PMID:
14633785
14.

Biphasic anti-osteoclastic action of intravenous alendronate therapy in multiple myeloma bone disease.

Kitano M, Ogata A, Sekiguchi M, Hamano T, Sano H.

J Bone Miner Metab. 2005;23(1):48-52.

PMID:
15616894
15.

[Bone mineral disorders in patients with multiple myeloma].

Przedlacki J, Paluszewska M, Ostrowski G, Paprocka E, Swieboda A, Niesiobedzka-Krezel J, Walter Z, Ostrowski K, Kuratowska Z.

Pol Tyg Lek. 1996 May;51(19-22):275-7. Polish.

PMID:
9289708
16.

In vivo measurement of bone mass in the radius.

Johnston CC Jr, Smith DM, Yu PL, Deiss WP Jr.

Metabolism. 1968 Dec;17(12):1140-53. No abstract available.

PMID:
5703479
17.

The method of minimization for allocation to clinical trials. a review.

Scott NW, McPherson GC, Ramsay CR, Campbell MK.

Control Clin Trials. 2002 Dec;23(6):662-74. Review.

PMID:
12505244
18.

Treatment of osteoporosis with fluoride.

Riggs BL, Jowsey J.

Semin Drug Treat. 1972 Summer;2(1):27-33. No abstract available.

PMID:
5048562
19.

Biochemical markers of bone disease in asymptomatic early stage multiple myeloma. A study on their role in identifying high risk patients.

Corso A, Arcaini L, Mangiacavalli S, Astori C, Orlandi E, Lorenzi A, Passamonti F, Klersy C, Pascutto C, Canevari-Sciorati A, Lazzarino M.

Haematologica. 2001 Apr;86(4):394-8.

20.

Frequency of hypercalcemia in patients of multiple myeloma in Karachi.

Mansoor S, Siddiqui I, Adil S, Kakapeto GN, Fatmi Z.

J Coll Physicians Surg Pak. 2005 Jul;15(7):409-12.

PMID:
16197869
Items per page

Supplemental Content

Write to the Help Desk